Deriv’s client-first philosophy earns the ‘Best Customer Service’ award at the Global Forex Awards, coinciding with its 25th year of empowering traders. 2024 is the year of wins for Deriv, which earlier this year won the ‘Most Trusted Broker’, ‘Best Trading Experience’ (LATAM) 2024, and ‘Best Latam Region Broker’ awards. Deriv receives Best Customer Service … Read more
AI-Media and Speechmatics Partnership AI-Media and Speechmatics today announce a strategic expansion of their multi-year partnership to deliver new and better AI-driven products to market. BROOKLYN, N.Y., Sept. 13, 2024 (GLOBE NEWSWIRE) — AI-Media – the global leader in audiovisual encoding technology and AI-driven transcription and translation solutions, and Speechmatics – the market leader in … Read more
AI-Media and Speechmatics Partnership AI-Media and Speechmatics today announce a strategic expansion of their multi-year partnership to deliver new and better AI-driven products to market. BROOKLYN, N.Y., Sept. 13, 2024 (GLOBE NEWSWIRE) — AI-Media – the global leader in audiovisual encoding technology and AI-driven transcription and translation solutions, and Speechmatics – the market leader in … Read more
AI-Media and Speechmatics Partnership AI-Media and Speechmatics today announce a strategic expansion of their multi-year partnership to deliver new and better AI-driven products to market. BROOKLYN, N.Y., Sept. 13, 2024 (GLOBE NEWSWIRE) — AI-Media – the global leader in audiovisual encoding technology and AI-driven transcription and translation solutions, and Speechmatics – the market leader in … Read more
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering … Read more
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering … Read more
